H.C. Wainwright analyst Ed Arce raised the firm’s price target on Travere Therapeutics to $20 from $19 and keeps a Buy rating on the shares following the “strong quarter” for Filspari.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics, Inc. (TVTX) Q2 Earnings Cheat Sheet
- Travere Therapeutics to Report Second Quarter 2024 Financial Results
- Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)